The latest Fact.MR research study offers oral antivirals demand outlook and studies growth opportunities in key segments, including type, drug class, disease indication, and distribution channel.
Branded Oral Antivirals Emerge as Top-choice for Treatment of Chronic Diseases
The latest Fact.MR research study offers oral antivirals demand outlook and studies growth opportunities in key segments, including type, drug class, disease indication, and distribution channel. The survey report also reveals key factors affecting the growth of the oral antivirals between 2021 and 2031
Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest Fact.MR market research study, the global oral antiviral market is poised to register impressive growth, generating revenue at an impressive pace during the forecast period (2021-2031). Rising burden of chronic diseases such as hepatitis, human immunodeficiency virus (HIV), and coronavirus has accelerated the demand for oral antivirals.
The market registered sales uptick due to the unprecedented outbreak of COVID-19 across the globe. As the cases surged, governments across the globe and private healthcare organizations increased the research & development activities to find the cure for the novel coronavirus.
Extensive research activities worldwide increased the demand for oral antivirals exponentially. Alongside this, increasing cases of HIV across spurred the sales of oral antivirals. Favorable government initiatives aimed at reducing the global burden of HIV also resulted in increased research activities for the development of novel drug treatment.
Request a report sample to gain comprehensive insights at
https://www.factmr.com/connectus/sample?flag=S&rep_id=5613
HIV continues to be a global burden and a major health issue, having claimed around 36.3 million lives across the globe so far, stated World Health Organization (WHO) in its latest issue of 2021. According to the UNAIDS, around 45.1 million people were affected with AIDS in 2020.
Besides this, surge in cases of novel coronavirus has compelled governments to increase their efforts in finding the cure of the virus. Countries such as India is still witnessing spike in the cases of COVID-19. So far, there are 220,563,227 confirmed cases across the globe, including 4,565,483 deaths registered as of 5th September 2021, states WHO.
With rising cases of such chronic diseases, government and healthcare institutes are doubling their efforts and increasing research activities to develop novel oral antivirals treatment. Thereby, creating lucrative growth opportunities for the market.
“Due to surging cases of COVID-19 and HIV, especially in countries such as India and the U.S., demand for oral antivirals have accelerated. On the back of this, preference for branded oral antivirals for the treatment of chronic ailments are creating remunerative growth opportunities for the market players,” says the Fact.MR analyst.
Key Takeaways from Oral Antivirals Market Survey
- Based on type, branded oral antivirals are expected to gain popularity during the forecast period
- Hepatitis segment is expected to witness highest growth, while coronavirus segment is anticipated to witness fastest growth backed by the surge in cases of COVID-19, especially in India
- Hospital pharmacies are expected to be the primary distribution channel of oral antivirals, however due to the growing shift of key companies towards online platforms, online pharmacies segment will witness significant boost
- India is expected to spearhead the growth of South Asia’s oral antivirals market, growth is driven by extensive research & development activities to reduce the COVID-19 cases
- China is expected to be the most lucrative country in East Asia market owing to the expansion of biologics market and growing research & development activities
- Backed by the expansion of healthcare infrastructure and growing demand for biosimilars, the U.S. will emerge as a potential market for oral antivirals key players
Key Drivers
- Surging demand for biosimilars for the treatment of chronic diseases such as influenza and coronavirus will improve the sales of oral antivirals
- High prevalence of chronic diseases and expansion of biologics market will bolster the market growth
- Rising awareness for self-administration and growing patient pool in home care setting will offer lucrative growth opportunities for oral antivirals market
Key Restraints
- Dearth of knowledge and efficacy due to the effect of oral drugs, resulting in first-pass metabolism is likely to hinder the growth
- Side-effects such as body-ache, high fever, nausea, and others are hampering the demand for oral antivirals
- Increased pricing pressure on the key companies and consumers is likely to impede the demand
To learn more about Oral Antivirals Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=AE&rep_id=5613
Competitive Landscape
Key companies are actively focusing on novel drug development and product launches to expand their product portfolio. Inorganic strategies such as mergers and collaborations are being adopted by key players to stay ahead in the competition.
Leading players are also actively participating in acquisitions of other key companies to increase their market penetration and gain competitive edge in the industry. For instance,
- In March 2021, Pfizer Inc. announced the initiation of its phase 1 study of its novel oral antiviral therapeutic agent against SARS-CoV-2. The trail is being conducted in the U.S. and has demonstrated potent in-vitro anti-viral activity against SARS-CoV-2, virus that causes COVID-19.
- In June 2021, Merck announced its agreement with the U.S. government for molnupiravir (MK-4482). Merck announced that molnupiravir is being evaluated in a Phase 3 clinical trial, MOVe-OUT study, for the treatment of non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes. The U.S. government is committed to purchase approximately 1.7 million courses of molnupiravir upon issuance and approval by the U.S. Food and Drug Administration (FDA).
- In October 2020, Roche announced its collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients.
Some of the leading oral antivirals providers profiled by Fact.MR are:
- Novartis AG
- Abbvie Inc.
- GlaxoSmithKline
- Merck & Co.Inc.
- Bristol-Myers Squibb Company
- Mylan N.V.
- Gilead Sciences Inc.
- Janssen Pharmaceuticals Inc.
- Appili Therapeutics
- Boston biotech Atea Pharmaceutical
More Valuable Insights on Oral Antivirals Market
Fact.MR, in its new report, offers an unbiased analysis of the global oral antivirals market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in the oral antivirals market with detailed segmentation:
By Type:
- Generic
- Branded
By Drug Class:
- Nucleoside reverse transcriptase inhibitors (NRTI)
- Neuraminidase inhibitor
- Nucleoside analogues of guanine
- Nucleoside analogues of thymidine
- Protease Inhibitors
- Nucleotide reverse transcriptase inhibitor (NtRTI)
- Combination Drugs
- Others
By Disease Indication:
- Influenza
- Hepatitis
- Human Immunodeficiency Virus (HIV)
- Coronavirus
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Key Questions Covered in the Oral Antivirals Market Report
- The report offers insight into oral antivirals demand outlook for 2021-2031
- The market survey also highlights projected sales growth for the oral antivirals market between 2021 and 2031
- Oral antivirals market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Oral antivirals market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain –
Respiratory Virus Vaccines Market- In recent years, the threat presented by avian influenza to the global population has likely reached an all-time high. The tightening noose of COVID-19, combined with the discovery of a slew of new respiratory viruses, underscores the need for therapeutic and preventive strategies to be developed. Developing vaccinations could be the most important step toward preventing widespread viral illnesses and lowering the mortality rate linked with them. With the current epidemic, demand for respiratory virus vaccinations is projected to increase dramatically.
Drug Discovery Services Market- The expansion of drug discovery services can be attributed to an increase in research and development efforts and expenditures, as well as leading pharmaceutical companies’ shift to outsourcing. The use of improved technology in the drug discovery process is also a major market growth factor. Regulatory initiatives toward pharmacogenomics technology, combinatorial chemistry technology, and other emerging trends in drug discovery technology are among the market’s forthcoming trends. There has also been a rise in the use of procedures that do not require the use of labels.
Extended Oral Antibiotics Market- Due to the increased number of total joint arthroplasties (hip (THA) and knee (TKA) arthroplasty) and cases of prosthetic joint infections, extended oral antibiotics are expected to have substantial demand in the market. Furthermore, rising R&D for preventing or controlling prosthetic joint infections, as well as the introduction of immunoparticles, nanoparticles, novel antibiotics, photodynamic therapy, antimicrobial peptides, and lytic bacteriophages, are some of the factors propelling the global extended antibiotics market forward.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR